Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Samsung Executive Cuong Do Joins the Company as Independent Board Member

May 04, 2016 (Marketwired via COMTEX) -- BEVERLY, MA--(Marketwired - May 04, 2016) - NanoAntibiotics, Inc. (otc pink:NNAB) (the "Company," soon to be known as BioVie Inc.), a development stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today the appointment of Cuong Do, MBA, as an independent member of the Company's Board of Directors. Mr. Do is currently Executive Vice President, Global Strategy Group for Samsung, where he helps to set the strategic direction for Samsung Group's diverse business portfolio.

As the former Chief Strategy Officer for Merck, a leading US pharmaceuticals company, and having successfully built and sold a biotechnology company, Mr. Do brings highly relevant experience to NanoAntibiotics (BioVie). Prior to Merck he was a senior partner at McKinsey & Company, where over 17 years he helped build the healthcare, high tech and corporate finance practices. Mr. Do holds an MBA from the Tuck School of Business at Dartmouth.

"Cuong is very impressive, as evident years ago when we attended business school together and more recently when he acted as an advisor and investor in LAT Pharma LLC (recently acquired by NanoAntibiotics). He brings remarkable business acumen and corporate strategy expertise to the Company," commented Jonathan Adams, MBA, CEO of the Company. "Cuong is committed to advancing our CIP Terlipressin Technology for the benefit of desperately ill patients, and to creating substantial value for our shareholders."

The Company's goal is to commence a clinical trial program as early as 2017 upon FDA acceptance of an Investigational New Drug...